Assignee
ONXEO
FR·5 granted patents·6 pending applications·6 citations·filing 2015–2021
Top patents by PatentIndex Score
11 records- 0188US10363317B2Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugatesONXEO·Filed 2017·Granted Jul 30, 2019·3 cites·15 claims
- 0283US10765758B2Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugatesONXEO·Filed 2019·Granted Sep 8, 2020·1 cites·18 claims
- 0375US10821128B2Treatment of cancer by systemic administration of Dbait moleculesONXEO·Filed 2017·Granted Nov 3, 2020·2 cites·13 claims
- 0455US11266614B2Oral formulations of belinostatONXEO·Filed 2018·Granted Mar 8, 2022·0 cites·11 claims
- 0554US2021023116A1Treatment of cancer by systemic administration of dbait moleculesONXEO·Filed 2020·Application pending·0 cites
- 0652US2023235327A1A dbait molecule in combination with kras inhibitor for the treatment of cancerONXEO·Filed 2021·Application pending·0 cites
- 0752US2022143049A1A dbait molecule in combination with kinase inhibitor for the treatment of cancerONXEO·Filed 2020·Application pending·0 cites
- 0849US2022054524A1New conjugated nucleic acid molecules and their usesONXEO·Filed 2019·Application pending·0 cites
- 0946US2020407720A1A dbait molecule against acquired resistance in the treatment of cancerONXEO·Filed 2019·Application pending·0 cites
- 1036US2020121699A1Combination therapies comprising immuno-oncology agents and belinostatONXEO·Filed 2017·Application pending·0 cites
- 1132US10675271B2Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapyONXEO·Filed 2015·Granted Jun 9, 2020·0 cites·12 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →